Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 10/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 3/20 | 0.41 |
| ▸ | PDE8A | O60658 | 2/20 | 0.41 |
| ▸ | CHKB | Q9Y259 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694118 | 0.86 | KMT2A (0.42) | GSK3BNT5EMEN1KMT2A | |
| SCHEMBL5694209 | 0.81 | GSK3B (0.61) | GSK3BMEN1KMT2A | |
| SCHEMBL5694208 | 0.79 | CFTR (0.53) | CFTRCDK1NT5EKMT2ACHKA | |
| SCHEMBL5694098 | 0.78 | XDH (0.54) | MEN1KMT2A | |
| SCHEMBL5694226 | 0.74 | CDK1 (0.59) | CFTRCDK1GSK3BCHKAPDE8A | |
| SCHEMBL29124866 | 0.70 | CDK1 (0.51) | CFTRCDK1NT5ECHKAPDE8A | |
| SCHEMBL5694096 | 0.70 | CDK1 (0.45) | CFTRCDK1GSK3BNT5EPDE8A | |
| SCHEMBL2060472 | 0.69 | PDE4A (0.67) | CDK1PDE8A | |
| SCHEMBL2385400 | 0.68 | TK1 (0.40) | MEN1KMT2A | |
| SCHEMBL17815797 | 0.68 | CFTR (0.67) | CFTRCDK1PDE8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | CFTR 4467/4885CDK1 447/4885GSK3B 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.